CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of several patents. The claims of these patents cover novel immune modulatory oligonucleotides (IMO) and chemical modifications of IMOs, each of which provide unique immune responses.
